News and Comments

Yesterday Market Performance Brings Back Hope in Normalcy. Compugen Announced Some Encouraging News.

  Thursday, October 08, 2015

Stories From Yesterday Market More...

XOMA: A New Chance for Resurrection?

  Friday, October 02, 2015
  • - Exclusively licenses global rights to its (TGFb) antibody program to Novartis 
  •  More...

EXELIXIS: The Stream Of Good News Continues to Flow

  Monday, September 28, 2015

Exelixis (EXEL) announced positive results from the METEOR Phase 3 Pivotal Trial of Cabozantinib in advanced renal cell carcinoma, which was presented at the European Cancer Congress 2015. In the study, Cabozantinib met the primary endpoint of improving progression-free survival as compared to Evorulimus.  More...

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of A Promising Glaucoma Drug

  Thursday, September 17, 2015

Aerie Pharmaceuticals (AERI), which is specialized in glaucoma treatments reported successful results of its second Phase 3 trial for Rhopressa™ — a novel once-daily, triple-action eye drops for glaucoma.   More...

Huge Improvement in the Differential Diagnosis of Diseases and More

  Wednesday, September 02, 2015

Biotechnology industry is proving to be the most innovative and the most growing among WallStreet industries. Individual biotech companies’ achievements complement each other. Some are evolving the sequencing of genes and genetic analysis, while others are excelling in designing drugs based on the tremendous amount of facts they are getting on root causes of the diseases and the interaction of proteins. The biotech companies have largely improved their drug discovery, design and development, including clinical trial plans and strategies.   More...

Why Switzerland Approval of Exelixis and Roche Drug Combination for melanoma is a Big Deal?

  Thursday, August 27, 2015


Seres Therapeutics: A novel Approach For Treating Clostridium Difficile infection.

  Friday, August 21, 2015

But First: Here is some Good News From  More...

KITE: News we are Anxious to Hear

  Monday, August 17, 2015

Kite Pharma (Kite) stock was sliding, raising concern about the firm and all the biotech firms that are designing and developing CAR T Cell immunotherapy treatments for cancer. Many investors are wondering about the plummeting of the stock and obviously others have learned about one death that occurred during clinical trial, which caused KITE selloff.    More...

Inovio is in Much Better Shape than Six Months Ago

  Thursday, August 13, 2015

INOVIO More...

AstraZeneca Selects Mirati Therapeutics Drug For Its cancer Immunotherapy Combination

  Thursday, August 06, 2015

In The NEWS More...

Recent Postings



GlycoMimetics (GLYN) ABBVIE (ABBV) Aimmune Therapeutics (AIMT) ADVENTRIX (ANX) SUNESIS PHARMACEUTICALS (SNSS) Trastuzumab-DM1 Prolor Biotech (PBTH) Agenus (AGEN) Incyte (INCY) Abbott Laboratories (ABT) Valeant Pharmaceuticals International (VRX) ZALTRAP™ Pluristem (PSTI) Rapamune AGOS (ARGS) OncoCyte (OCX) VANDA (VNDA) Akebia Therapeutics (AKAB) KERYX (KERX) Agenus (AGEN Anadys (ANDS) Editas (EDIT) KITE (KITE) Human Genome Sciences (HGSI) Regeneron (REGN) JOUNCE THERAPEUTICS (JNCE) AstraZeneca (AZN) Elan (ELN) CompuGen (CGEN) Roche (ROCHE) PTC Therapeutics (PTCT) Dynavax (DVAX) Sanofi (SNA) SERES THERAPEUTICS (MCRB) Multiple Myeloma SYNTA (SNTA) Gilead (GILD) Biogen Idec (BIIB) Ziofpharm (ZIOP) Jazz Pharmaceuticals (JAZZ) PORTOLA (PTLA) Intercept (ICPT) HALOZYME (HALO) Galena (GALE) Merck (MRK) Sanofi (SNY) Ariad (ARIA) Intermune (ITMN) Sequenom (SQNM) Anacor (ANAC) Intrexon (XON) GlaxoSmithKline (GSK) Onyx (ONXX) Telaprevir IDERA (IDRA) BIOMARIN (BMRN) NEKTAR (NKTR)) ARCA (ABIO) Endometrial Cancer C4 Therapeutics Herceptin Bristol-Myers Squibb (BMY) OSI (OSIP) Illumina (ILMN) INNOVIVA (INVA) Sanofi-Aventis (SAN) Roche (RHHBY) NANTKWEST (NK) Dendreon (DNDN) GUARDIAN HEALTH Benlysta (belimumab) Sarepta (SRPT) Mirati Therapeutics (MRTX) Sangamo (SGMO) Global Cell Therapeutics (GBT) MODERNA Micromet (MITI) Alder Biopharmaceuticals (ALDR) Ionis (IONS) Theravance (THRX) RenenxBio (RGNX) ACADIA (ACAD) Idenix (IDIX) ImmunoGen (IMGN) Epizyme (EPZM) REGULUS (RGLS) Bellicum (BLCM) Spike Therapeutics (ONCE) galapagos (GLPG) Genentech Ocular Therapeutix (OCUL) Theravance Bio Pharma (TBPH) NEUROCRINE (NBIX) Zerenex JUNO (JUNO) Velcade (bortezomib) Cytokinetics (CYTK) Biocryst (BCRX) TOKAI (TKAOI) ARGOS (ARGS) Xoma (XOMA) Vitae Pharmaceuticals (VTAE) Ridaforolimus Revlimid (lenolidamide) Amgen (AMGN) Inovio (INO) Exelixis (EXEL) ISIS (ISIS) CRISPR Therapeutics (CRSP) Prosensa (RNA) Alnylam (ALNY) Advaxis (ADXS) Seattle Genetics (SGEN) Vertex (VRTX) Adaptimmune (ADAP) NOVOCURE (NVCR) LEXICON (LXRX) Tysabri CEMPRA (CEMP) Auspex (ASPX) AERIE PHARMACEUTICALS Array Pharmaceuticals (ARRY) Human Longevity (HLI)